SelfDecode is a broad health-genetics subscription that includes a pharmacogenetics report. Here is how it compares to Gene2Rx's focused pharmacogenetic analysis.
Last updated: 2026-04-22
| Feature | Gene2Rx | SelfDecode |
|---|---|---|
| Pricing model | One-time report purchase from $5 to $49 | Subscription, typically $59/month or around $149 to $199 per year for core plans (premium tiers higher) |
| Primary focus | Pharmacogenetics (103 medications with CPIC/FDA guidance) | Broad health-genetics platform. Pharmacogenomics is one report among many (supplements, health traits, longevity, ancestry-adjacent) |
| Clinical guideline anchoring | Every recommendation traceable to CPIC or FDA published guideline | AI-driven interpretation across peer-reviewed studies, not strictly CPIC-anchored; breadth over depth |
| Uses existing 23andMe / AncestryDNA data | Yes, upload raw data | Yes, upload raw data (or use SelfDecode's own DNA kit) |
| Pharmacogenes covered | CYP2D6, CYP2C19, CYP2C9, CYP3A5, CYP2B6, CYP1A2, SLCO1B1, VKORC1, DPYD, TPMT, UGT1A1, HLA-B, HLA-A | Wide set of SNPs across many genes; interpretation is SNP-level rather than star-allele / phenotype-level |
| Star alleles and diplotypes | Yes, resolves proper CYP2D6 star alleles and calls metabolizer phenotypes per CPIC | Generally SNP-level interpretations rather than clinical-grade star-allele resolution |
| Report output | Per-drug recommendation with evidence grade and CPIC / FDA source link | AI-generated summaries and gene-by-gene SNP commentary, often alongside supplement suggestions |
| Supplement recommendations | Not included. This is a medication-focused tool, not a supplement service | Heavily featured. SelfDecode sells its own supplement line and ties genetic results to supplement recommendations |
| Ongoing commitment | None. Buy the report once | Subscription required to access reports. Canceling the subscription typically stops access to the interpretations |
SelfDecode is a direct-to-consumer health-genetics platform. It accepts uploads from 23andMe, AncestryDNA, MyHeritage, and other consumer genotyping services, or sells its own DNA test kit. What you get in return is a subscription-based interface that surfaces many different reports from the same underlying data: health-risk analyses, trait associations, ancestry-adjacent features, longevity scores, supplement recommendations, and a pharmacogenomics section.
This breadth is a feature for users who want one service to explore every angle of their genetic data. It is also why SelfDecode's pharmacogenomics section is different in character from a dedicated pharmacogenetic test like Gene2Rx. Pharmacogenomics is one report among many on SelfDecode, built using the same AI interpretation engine that drives the rest of the platform. Gene2Rx, by contrast, does only pharmacogenetics, and its methodology is specifically anchored to CPIC and FDA clinical guidelines.
SelfDecode prices as a subscription. Entry-level plans have historically been around $59 per month, with annual plans in the $149 to $199 range. Premium plans with more detailed reports and deeper trait analyses cost more. Canceling your subscription typically stops your access to the interpretations, though your original raw data remains yours.
Gene2Rx is priced as a one-time report purchase, starting at $5 for a starter report and up to around $49 for the comprehensive report. You pay once, you keep the report. There is no recurring fee and no ongoing relationship required. For users who specifically want pharmacogenetic information and do not want to pay indefinitely for a broader health-genetics platform they may not use, the one-time model is usually more cost-efficient.
The model difference matters for long-term cost. A SelfDecode annual subscription at $150 to $200 is several times the cost of a Gene2Rx report, and the charge continues year after year. If you want pharmacogenetic information and you do not want the other SelfDecode features (supplement recommendations, longevity scores, trait analyses), you are paying for things you are not using.
This is the most important difference between the two services and it is often the one users do not think about before choosing.
Gene2Rx grounds every drug recommendation in a specific CPIC or FDA published guideline. If the report says 'CYP2C19 poor metabolizer: consider alternative antidepressant,' that recommendation is traceable back to a specific peer-reviewed clinical guideline published by the Clinical Pharmacogenetics Implementation Consortium. The report shows the source.
SelfDecode's interpretation engine works differently. It draws from a large database of research studies (thousands of papers) and uses AI to surface patterns in that literature for each user's genotype. The breadth is real, and many of SelfDecode's interpretations are informative. The tradeoff is that interpretations are not strictly filtered to CPIC-graded clinical guidelines. A SelfDecode pharmacogenomics report will include more granular SNP-level observations, but some of those observations are based on individual studies rather than the multi-study consensus that CPIC requires before issuing a dosing recommendation.
For a clinician deciding a dose, CPIC-anchored recommendations are the standard. For an enthusiast exploring what individual genetic variants mean across many studies, SelfDecode's broader interpretation is appealing. These are different jobs.
Clinical pharmacogenetics relies on star allele nomenclature: CYP2D6 *1/*4, CYP2C19 *1/*17, etc. A star allele is not a single SNP but a combination of variants that collectively define a version of the gene and, by extension, a metabolizer phenotype. CPIC and every clinical pharmacogenetic test use star allele language because it maps directly to clinical recommendations.
Gene2Rx resolves star alleles from the raw SNP data in your 23andMe or AncestryDNA file where possible and calls metabolizer phenotypes per CPIC. For complex genes like CYP2D6 this is nontrivial work, and getting it right matters clinically.
SelfDecode's pharmacogenomics reports typically present SNP-level interpretations rather than resolved star alleles. This is informative in its own way but does not map as cleanly to the clinical prescribing language that CPIC publishes. A clinician reading a SelfDecode report alongside a CPIC guideline will have to translate between the two. A clinician reading a Gene2Rx report will see the same language CPIC uses.
SelfDecode has an in-house supplement product line. Genetic results frequently route users toward supplement recommendations that SelfDecode itself sells. This is a legitimate business model but it is also a conflict to be aware of. The clinical evidence for many genotype-guided supplement recommendations is thin, and several claims around supplements and common variants (for example, MTHFR variants and methylated folate supplementation) go beyond what peer-reviewed guidelines support.
Gene2Rx does not sell supplements. We report on medications where CPIC or FDA has published pharmacogenetic guidance, and we do not route users toward commercial products beyond the option to upgrade the report itself. If supplement recommendations are what you want, SelfDecode will provide them. If you want the commercial layer out of the way so the pharmacogenetic information stands alone, Gene2Rx is a different product.
SelfDecode's pharmacogenomics section covers a broad and variable set of medications depending on the subscription tier and the latest updates to the platform. Exact medication counts are not always published, but coverage leans toward common prescription drugs across psychiatry, cardiology, pain, and general practice.
Gene2Rx covers 103 medications specifically chosen because CPIC or FDA has published pharmacogenetic guidance for them. That includes psychiatric medications (SSRIs, TCAs, antipsychotics), cardiology (clopidogrel, warfarin, statins, metoprolol), pain management (codeine, tramadol, NSAIDs, opioids), oncology (capecitabine, fluorouracil, tamoxifen, mercaptopurine, azathioprine, irinotecan), immunosuppressants (tacrolimus), infectious disease (abacavir, efavirenz, voriconazole), and several other categories. Every one of those medications has a guideline-backed recommendation tied to a specific metabolizer phenotype.
SelfDecode makes sense for specific users. If you want a broad health-genetics platform and you value the full suite of reports (health traits, longevity, ancestry-adjacent features, supplement recommendations), the subscription model is what that costs. If you are an enthusiast who enjoys exploring granular SNP-level interpretations across many studies, SelfDecode's interface supports that exploration better than a focused pharmacogenetic tool. If you are actively taking supplements and you want genotype-tied supplement recommendations, SelfDecode offers that bundled with pharmacogenomics.
The situations where Gene2Rx is the better fit: you want pharmacogenetic information specifically, not a broader health-genetics platform. You want your recommendations anchored to CPIC and FDA guidelines rather than AI-synthesized study summaries. You prefer a one-time purchase to a recurring subscription. You want star-allele resolution and clinical-grade metabolizer phenotype calling. You want the report to be something you can hand to a clinician without translation.
SelfDecode includes a pharmacogenomics report as one of many features on its platform. It is not a dedicated pharmacogenetic test in the way Gene2Rx, GeneSight, or Genomind are. The pharmacogenomics section shares an interpretation engine with the rest of SelfDecode's health-trait reports, which means it is broader in scope but less tightly anchored to CPIC clinical guidelines.
Gene2Rx is cheaper if you just want pharmacogenetic information. A one-time Gene2Rx report is $5 to $49 and you keep it forever. SelfDecode is a subscription, typically $149 to $199 per year for annual plans and higher for premium tiers. Over even one year Gene2Rx is usually less than a third of SelfDecode's cost. Over multiple years the gap grows substantially. SelfDecode is only cheaper on a per-report basis if you actively use many of SelfDecode's other features.
It can be. The underlying DNA data is the same regardless of which service interprets it, so metabolizer status identified by SelfDecode is not inaccurate. What SelfDecode does differently is present interpretations at the individual SNP level using an AI-driven study database rather than resolving clinical star alleles and mapping them to CPIC-graded dosing guidelines. For sharing with a prescribing clinician, a CPIC-anchored report like Gene2Rx translates more directly into clinical prescribing workflow.
You could. Some users keep a SelfDecode subscription for the broader health-genetics features and use Gene2Rx separately for a CPIC-anchored pharmacogenetic report they can share with their doctor. If cost is a consideration, the cleaner approach is to pick the product that matches what you actually want: Gene2Rx if you want pharmacogenetics specifically, SelfDecode if you want the broader platform.
No. Both Gene2Rx and SelfDecode are direct-to-consumer and do not require a prescriber. This is a shared strength relative to clinical tests like GeneSight or Genomind. The difference between Gene2Rx and SelfDecode is not about provider access, it is about product focus and pricing model.
SelfDecode sells supplements and routes genetic results toward its own product line. That is a commercial incentive that should inform how you weight the recommendations. The clinical evidence supporting many genotype-tied supplement suggestions is thinner than the evidence behind pharmacogenetic dosing of prescription drugs. If supplement guidance is what you want, SelfDecode provides it. If you want clean pharmacogenetic information without a commercial supplement layer, Gene2Rx is a different product.
Gene2Rx turns your existing 23andMe, AncestryDNA, MyHeritage, or whole-genome data into a CPIC-anchored pharmacogenetic report. One-time pricing from $5 to $49. No subscription. No supplements.
Get your Gene2Rx report Look up a medication firstInformational only, not medical advice. Every pharmacogenetic test has a role; the right choice depends on your situation, insurance, and the medications you're evaluating. Always discuss pharmacogenetic results with your prescribing clinician before making any medication change.